Advances and controversies in urologic oncology:
Gespeichert in:
| Format: | Buch |
|---|---|
| Sprache: | English |
| Veröffentlicht: |
Philadelphia [u.a.]
Saunders
1995
|
| Schriftenreihe: | Surgical oncology clinics of North America
4,2 |
| Schlagworte: | |
| Online-Zugang: | Inhaltsverzeichnis |
| Beschreibung: | XVII S., S. 189 - 376 Ill., graph. Darst. |
Internformat
MARC
| LEADER | 00000nam a2200000 cb4500 | ||
|---|---|---|---|
| 001 | BV010216486 | ||
| 003 | DE-604 | ||
| 005 | 00000000000000.0 | ||
| 007 | t | ||
| 008 | 950609s1995 ad|| |||| 00||| engod | ||
| 035 | |a (OCoLC)32417530 | ||
| 035 | |a (DE-599)BVBBV010216486 | ||
| 040 | |a DE-604 |b ger |e rakddb | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-12 | ||
| 245 | 1 | 0 | |a Advances and controversies in urologic oncology |c Philip J. Walther, guest ed. |
| 264 | 1 | |a Philadelphia [u.a.] |b Saunders |c 1995 | |
| 300 | |a XVII S., S. 189 - 376 |b Ill., graph. Darst. | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b n |2 rdamedia | ||
| 338 | |b nc |2 rdacarrier | ||
| 490 | 1 | |a Surgical oncology clinics of North America |v 4,2 | |
| 650 | 2 | |a Tumeurs de l'appareil urogénital | |
| 650 | 2 | |a Tumeurs urologiques | |
| 650 | 4 | |a Urogenital Neoplasms |x therapy | |
| 650 | 4 | |a Urologic Neoplasms |x surgery | |
| 650 | 0 | 7 | |a Urogenitalkrebs |0 (DE-588)4133891-1 |2 gnd |9 rswk-swf |
| 655 | 7 | |0 (DE-588)4143413-4 |a Aufsatzsammlung |2 gnd-content | |
| 689 | 0 | 0 | |a Urogenitalkrebs |0 (DE-588)4133891-1 |D s |
| 689 | 0 | |5 DE-604 | |
| 700 | 1 | |a Walther, Philip J. |e Sonstige |4 oth | |
| 830 | 0 | |a Surgical oncology clinics of North America |v 4,2 |w (DE-604)BV007071205 |9 4,2 | |
| 856 | 4 | 2 | |m HBZ Datenaustausch |q application/pdf |u http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=006789326&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |3 Inhaltsverzeichnis |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-006789326 | ||
Datensatz im Suchindex
| _version_ | 1804124624792846336 |
|---|---|
| adam_text | j ADVANCES AND CONTROVERSIES IN UROLOGIC ONCOLOGY
CONTENTS
Foreword xiii
Blake Cady
Preface xv
Philip J. Walther
Bacillus Calmette Guerin Immunotherapy for Superficial
Bladder Cancer: New Prospects for an Old Warhorse 189
Michael A. O Donnell and William C. DeWolf
The intravesical instillation of live bacillus Calmette Guerin (BCG)
for bladder cancer therapy is one of the most successful examples
of immunotherapy today. Despite its intrinsic toxicities, live BCG
holds even greater promise as methods are developed to manip¬
ulate both its immunotherapeutic and biologic properties geneti¬
cally.
Gene Therapy Approaches in Urologic Oncology 203
Johannes Vieweg and Eli Gilboa
The genetic modification of tumor cells to secrete cytokines poten¬
tially is a useful tool for the urologic oncologist. Preclinical studies
using improved animal models for bladder, renal, and prostate
cancer demonstrate not only the efficacy of such treatment but also
the technical feasibility to achieve long term expression of cyto¬
kines in human cancer cells. These studies form the basis to pursue
the clinical exploration of cytokine gene based immunotherapy in
urologic cancers.
| SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA
VOLUME 4 • NUMBER 2 • APRIL 1995 vii
Renal Cell Carcinoma: Molecular Genetics and
Clinical Implications 219
Scott B. Jennings, James R. Gnarra, McClellan M. Walther,
Berton Zbar, and W. Marston Linehan
Recent advances in the molecular genetics of renal cancer have led
to the identification of a new tumor suppressor gene, the VHL
gene. This article discusses the role of the VHL gene in the cause
of sporadic and familial forms of renal cell carcinoma and the roles
of other tumor suppressor genes and chromosomal abnormalities.
It is hoped that greater understanding of the mechanisms of inac
tivation of the VHL gene and its product will lead to improvements
in diagnosis and treatment of sporadic and familial renal malig¬
nancies.
Tumor Suppressor Gene Alterations in Bladder Carcinoma:
Translational Correlates to Clinical Practice 231
Guido Dalbagni, Carlos Cordon Cardo, Victor Reuter, and
William R. Fair
The most common tumor suppressor genes involved in the pre¬
diction of bladder tumor progression are the Rb and the p53 genes.
This article summarizes current data on the use of these markers
in prognostic evaluation.
Genetic Alterations in Prostate Adenocarcinoma 241
Neal J. Prendergast and Philip J. Walther
The genetic alterations associated with prostate carcinogenesis, its
progression, and the emergence of androgen independence grad¬
ually are being defined. This article focuses on a number of genetic
defects that have been identified in prostate cancer, specifically as
they relate to disease progression, radiation resistance, and andro¬
gen independence.
The Association of Oncogenic Human Papillomaviruses with
Urologic Malignancy: The Controversies and Clinical
Implications 257
John S. Wiener and Philip J. Walther
Sexually transmitted human papillomaviruses (HPV) are linked to
both benign and malignant lesions of the genitourinary tract. Evi¬
dence links oncogenic HPV types with carcinomas of the penis and
urethra. An association with other common sites of urologic
malignancies (prostate, bladder) is controversial. Whereas the
screening of sexually active females for HPV has received sub
viii contents
I
stantial attention, the presence of a potential male carrier state has
received little scrutiny. Systemic immunotherapies based on ex¬
pression of HPV related proteins by infected or transformed hu¬
man epithelia, however, may be possible in the near future.
Continent and Orthotopic Urinary Diversion Following
Radical Cystectomy: Should These Reconstructive
Procedures Now Be Considered Standard of Care? 277
Stuart D. Boyd, Eila Skinner, Gary Lieskovsky, and
Donald G. Skinner
From 1982 to 1994, over 1000 cystectomy patients underwent con¬
tinent cutaneous diversion or orthotopic reconstruction at the Uni¬
versity of Southern California School of Medicine. Short and long
term results showed the cost of these diversions to the patient is
no greater than that associated with an ileal conduit, and the ben¬
efits of these procedures in terms of improved quality of life are
immeasurable. Increasingly, orthotopic reconstruction is becoming
the procedure of choice for most patients, both male and female.
Adjuvant Chemotherapy for Bladder Cancer:
Standard of Care or Unproven Therapy? 287
Robert R. Bahnson, David Smith, and Donald Trump
The failure of radical cystectomy to cure the majority of patients
with muscle invasive transitional cell carcinoma of the bladder has
prompted clinical trials evaluating adjuvant chemotherapy. No
properly conducted prospective trials are available to support un¬
equivocally the application of pre or postsurgical chemotherapy.
A large trial comparing chemotherapy with no chemotherapy and
standard treatment (cystectomy) is nearing completion. The results
will determine whether or not adjuvant chemotherapy becomes the
standard of care.
Conservative Renal Surgery: Has It a
Role in Renal Cell Carcinoma? 295
Thomas E. Keane and Sam D. Graham, Jr
Conservative renal surgery is a viable alternative for patients in
whom preservation of renal function is important. The long term
survival is similar to that of radical nephrectomy, especially in low
grade malignancies. The technique is unproven in patients with a
normally functioning contralateral renal unit, although it may be
an option in small, peripheral, low grade lesions.
CONTENTS ix
Laparoscopic Urologic Surgery: The Financial Realities 307
Howard N. Winfield, James F. Donovan, Scott A. Troxel,
and Thomas M. Rashid
Since 1990, laparoscopic surgery has gained an important role in
the specialty of urology. This article provides a financial analysis
of the three most common urolaparoscopic procedures compared
with their open surgical counterpart. The intraoperative costs of
laparoscopic surgery are more expensive, but the postoperative ex¬
penses are less compared with open surgery. The financial rami¬
fications of a shorter period of convalescence following laparo¬
scopic surgery must be considered.
Prostate Cancer Screening: Why the Controversy? 315
Philip J. Walther
The development of new technologies has stimulated a crusade of
screening for earlier detection of prostate cancer. This effort has
resulted in controversy regarding its clinical use in this format.
Until randomized clinical screening trials define the value of pros¬
tate cancer screening, clinicians who use screening approaches
must gain a strong understanding of the natural history of the dis¬
ease, the strengths and weaknesses of available screening meth¬
odologies, and epidemiologic considerations of prostate cancer
risk.
The Impact of PSA on Prostate Cancer Management:
Can We Abandon Routine Staging Pelvic Lymphadenectomy? 335
Jeffrey R. Gingrich and David F. Paulson
Despite a negative metastatic evaluation, up to 100% of patients
with high grade tumors are found to harbor metastatic disease
within the pelvic lymph nodes at the time of surgery. This article
reviews the literature regarding efforts to refine noninvasive pre
operative staging through the use of serum tumor markers, im¬
proved radiologic imaging, and histologic analysis of the biopsy
specimens. A discussion of the renewed controversy regarding the
role of pelvic lymphadenectomy in the management of adenocar
cinoma of the prostate follows.
X CONTENTS
Controversies in the Treatment of Prostate Cancer With
Maximal Androgen Deprivation 345
David G. McLeod and Judd W. Moul
The concept of maximal androgen deprivation (MAD) has become
the accepted therapy for metastatic prostate cancer. MAD is also
under investigation as neoadjuvant therapy prior to radical pros¬
tatectomy and radiation therapy. Innovative new approaches, such
as intermittent androgen deprivation and new combination ther¬
apies, will emerge over the next decade.
Computer Modeling of Prostate Cancer Treatment:
A Paradigm for Oncologic Management? 361
Brian J. Miles and Michael W. Kattan
This article discusses the relevance of computer modeling to the
management of prostate cancer. Several computer modeling tech¬
niques are reviewed and the advantages and disadvantages of each
are discussed. An example that uses a computer model to compare
alternative strategies for clinically localized prostate cancer is
examined in detail. The quality of the data used in computer
models is critical, and these models play an important role in med¬
ical decision making.
Index 373
Subscription Information Inside back cover
CONTENTS Xi
|
| any_adam_object | 1 |
| building | Verbundindex |
| bvnumber | BV010216486 |
| ctrlnum | (OCoLC)32417530 (DE-599)BVBBV010216486 |
| format | Book |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01495nam a2200373 cb4500</leader><controlfield tag="001">BV010216486</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">00000000000000.0</controlfield><controlfield tag="007">t</controlfield><controlfield tag="008">950609s1995 ad|| |||| 00||| engod</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)32417530</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV010216486</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rakddb</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-12</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Advances and controversies in urologic oncology</subfield><subfield code="c">Philip J. Walther, guest ed.</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Philadelphia [u.a.]</subfield><subfield code="b">Saunders</subfield><subfield code="c">1995</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">XVII S., S. 189 - 376</subfield><subfield code="b">Ill., graph. Darst.</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="1" ind2=" "><subfield code="a">Surgical oncology clinics of North America</subfield><subfield code="v">4,2</subfield></datafield><datafield tag="650" ind1=" " ind2="2"><subfield code="a">Tumeurs de l'appareil urogénital</subfield></datafield><datafield tag="650" ind1=" " ind2="2"><subfield code="a">Tumeurs urologiques</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Urogenital Neoplasms</subfield><subfield code="x">therapy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Urologic Neoplasms</subfield><subfield code="x">surgery</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Urogenitalkrebs</subfield><subfield code="0">(DE-588)4133891-1</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="655" ind1=" " ind2="7"><subfield code="0">(DE-588)4143413-4</subfield><subfield code="a">Aufsatzsammlung</subfield><subfield code="2">gnd-content</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Urogenitalkrebs</subfield><subfield code="0">(DE-588)4133891-1</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Walther, Philip J.</subfield><subfield code="e">Sonstige</subfield><subfield code="4">oth</subfield></datafield><datafield tag="830" ind1=" " ind2="0"><subfield code="a">Surgical oncology clinics of North America</subfield><subfield code="v">4,2</subfield><subfield code="w">(DE-604)BV007071205</subfield><subfield code="9">4,2</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">HBZ Datenaustausch</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=006789326&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-006789326</subfield></datafield></record></collection> |
| genre | (DE-588)4143413-4 Aufsatzsammlung gnd-content |
| genre_facet | Aufsatzsammlung |
| id | DE-604.BV010216486 |
| illustrated | Illustrated |
| indexdate | 2024-07-09T17:48:38Z |
| institution | BVB |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-006789326 |
| oclc_num | 32417530 |
| open_access_boolean | |
| owner | DE-12 |
| owner_facet | DE-12 |
| physical | XVII S., S. 189 - 376 Ill., graph. Darst. |
| publishDate | 1995 |
| publishDateSearch | 1995 |
| publishDateSort | 1995 |
| publisher | Saunders |
| record_format | marc |
| series | Surgical oncology clinics of North America |
| series2 | Surgical oncology clinics of North America |
| spelling | Advances and controversies in urologic oncology Philip J. Walther, guest ed. Philadelphia [u.a.] Saunders 1995 XVII S., S. 189 - 376 Ill., graph. Darst. txt rdacontent n rdamedia nc rdacarrier Surgical oncology clinics of North America 4,2 Tumeurs de l'appareil urogénital Tumeurs urologiques Urogenital Neoplasms therapy Urologic Neoplasms surgery Urogenitalkrebs (DE-588)4133891-1 gnd rswk-swf (DE-588)4143413-4 Aufsatzsammlung gnd-content Urogenitalkrebs (DE-588)4133891-1 s DE-604 Walther, Philip J. Sonstige oth Surgical oncology clinics of North America 4,2 (DE-604)BV007071205 4,2 HBZ Datenaustausch application/pdf http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=006789326&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA Inhaltsverzeichnis |
| spellingShingle | Advances and controversies in urologic oncology Surgical oncology clinics of North America Tumeurs de l'appareil urogénital Tumeurs urologiques Urogenital Neoplasms therapy Urologic Neoplasms surgery Urogenitalkrebs (DE-588)4133891-1 gnd |
| subject_GND | (DE-588)4133891-1 (DE-588)4143413-4 |
| title | Advances and controversies in urologic oncology |
| title_auth | Advances and controversies in urologic oncology |
| title_exact_search | Advances and controversies in urologic oncology |
| title_full | Advances and controversies in urologic oncology Philip J. Walther, guest ed. |
| title_fullStr | Advances and controversies in urologic oncology Philip J. Walther, guest ed. |
| title_full_unstemmed | Advances and controversies in urologic oncology Philip J. Walther, guest ed. |
| title_short | Advances and controversies in urologic oncology |
| title_sort | advances and controversies in urologic oncology |
| topic | Tumeurs de l'appareil urogénital Tumeurs urologiques Urogenital Neoplasms therapy Urologic Neoplasms surgery Urogenitalkrebs (DE-588)4133891-1 gnd |
| topic_facet | Tumeurs de l'appareil urogénital Tumeurs urologiques Urogenital Neoplasms therapy Urologic Neoplasms surgery Urogenitalkrebs Aufsatzsammlung |
| url | http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=006789326&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |
| volume_link | (DE-604)BV007071205 |
| work_keys_str_mv | AT waltherphilipj advancesandcontroversiesinurologiconcology |